UNITY Biotechnology Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Diabetic Macular Edema
About The Event
UNITY will host a program update on UBX1325 and BEHOLD, the Phase 2 trial in diabetic macular edema (DME). Key Opinion Leader (KOL) Arshad M. Khanani, MD, MA, FASRS (Director of Clinical Research, Sierra Eye Associates), and members of the UNITY senior management team will lead the discussion.
UBX1325 is currently being evaluated for the treatment of age-related diseases of the eye – including DME and age-related macular degeneration, and is not approved for any use in any country. UBX1325 is a potent small-molecule inhibitor of Bcl-xL, a member of the Bcl-2 family of apoptosis regulating proteins. UBX1325 is designed to inhibit the function of proteins that senescent cells rely on for survival.
A live Q&A session will follow the formal presentations.